Patents Examined by Taylor V. Oh
  • Organic compounds
    Patent number: 11773095
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: October 3, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • Toxic aldehyde related diseases and treatment
    Patent number: 11771664
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: October 3, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Solid form of (-)-Ambrox formed by a bioconversion of homofarnesol in the presence of a biocatalyst
    Patent number: 11773419
    Abstract: A solid form of (?)-Ambrox formed by a bioconversion process.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: October 3, 2023
    Assignee: Givaudan SA
    Inventors: Ghislain Sanhaji, Alix Rousseaux, Sandrine Noel, Eric Eichhorn
  • Composition containing hesperetin and synergistic hypoglycemic application thereof
    Patent number: 11771679
    Abstract: The present invention discloses a composition containing hesperetin and synergistic hypoglycemic application thereof, and belongs to the technical field of natural active compounds. The composition of the present invention contains the hesperetin and a compound X, and the compound X is galangin or formononetin, where a mass ratio of the hesperetin to the galangin is 30:100, and a mass ratio of the hesperetin to the formononetin is 30:20. The composition of the present invention has an obvious synergistic effect of inhibiting ?-glucosidase, and the effect thereof is better than that of using the flavonoid compound alone, and may reduce a dosage of the use of drugs and occurrence of drug resistance.
    Type: Grant
    Filed: December 15, 2022
    Date of Patent: October 3, 2023
    Assignee: ZHENGZHOU FRUIT RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Qiang Zhang, Zhonggao Jiao, Dalei Chen, Jiechao Liu, Wenbo Yang, Chunling Zhang, Hui Liu, Zhenzhen Lv, Junkun Pan
  • Naphthalenesulfonamide compound, preparation method, and application
    Patent number: 11773057
    Abstract: Disclosed in the present invention are a naphthalenesulfonamide compound, a preparation method, and an application. The naphthalenesulfonamide compound provided by the present invention can interfere with Keap1-Nrf2 binding and activate Nrf2 to relieve inflammatory damage and improve an inflammatory microenvironment, has a potential anti-inflammatory activity, and can be used for preparing an anti-inflammatory drug for inflammatory damage of various inflammation-related diseases, including chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, intestinal Inflammations, rheumatoid arthritis, etc.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: October 3, 2023
    Assignee: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Qidong You, Zhengyu Jiang, Yuting Liu, Mengchen Lu, Hongli Shao, Jing Zhao, Xiaoli Xu, Xiaoke Guo, Lei Wang
  • Compounds for inhibiting TNIK and medical uses thereof
    Patent number: 11767297
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: September 26, 2023
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Compounds and compositions for treating conditions associated with NLRP activity
    Patent number: 11760735
    Abstract: In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: September 19, 2023
    Assignee: Novartis AG
    Inventors: Gary Glick, Shomir Ghosh, William R. Roush
  • ?-8-tetrahydrocannabinol from cannabidiol extracted from hemp
    Patent number: 11753390
    Abstract: The present invention describes a process to isomerize industrial hemp derived Cannabidiol (CBD) to a pure ?8-tetrahydrocannabinol (?8-THC) extract. This procedure will produce ?8-tetrahydrocannabinol that is essentially free from any detectable levels of ?9-tetrahydrocannabinol (?9-THC). Included in this filing are methods and processes to scale the reaction from the lab to process to large scale manufacturing. Additionally, the resulting extract from said methods and processes consists of higher purity than previously reported in the art and greater efficiency compared to prior art.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: September 12, 2023
    Inventors: Kyle Olson, Mario Tremblay
  • Inhibitors of microbially induced amyloid
    Patent number: 11744820
    Abstract: The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: September 5, 2023
    Assignees: Axial Therapeutics, Inc., California Institute of Technology
    Inventors: Timothy Sampson, Sarkis Mazmanian, Anthony Stewart Campbell
  • HDAC inhibitors and therapeutic methods using the same
    Patent number: 11739064
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: August 29, 2023
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Irina Gaisina
  • 6-chromanol derivatives for use as a medicament
    Patent number: 11730741
    Abstract: The present invention relates to the (S) enantiomeric form of certain 6-chromanol derivatives for use as a medicament. Especially, the present invention relates to the (S) enantiomeric form of a 6-chromanol derivative for use as a medicament wherein said 6-chromanol derivative is chosen from the group consisting of (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone; N-(benzyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; N-(phenyl)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamide; methyl 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)benzoate; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(morpholino)methanone, and pharmaceutically acceptable salts or bases thereof and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: August 22, 2023
    Assignee: SULFATEQ B.V.
    Inventors: Robert Henk Henning, Gerrit Jan Willem Euverink, Guido Krenning, Adrianus Cornelis Van der Graaf
  • Processes for the preparation of alkyl furans using bifunctional copper catalysts
    Patent number: 11718598
    Abstract: The present disclosure relates to the selective hydrodeoxygenation (HDO) of bio-based furanic ketones with a bifunctional copper-based catalyst in the presence of a solvent to prepare alkyl furans with high yield, purity, and scalability. The alkyl furans prepared herein are useful in the preparation of surfactants.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: August 8, 2023
    Assignee: Triad National Security, LLC
    Inventors: Andrew Sutton, Xiaokun Yang, Cameron M. Moore
  • (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist
    Patent number: 11718582
    Abstract: The following invention relates to (R)-4-(1-(1-(4-(trifluoromethyl)benzyl) pyrrodiline-2-carboxamide) cyclopropyl benzoic acid (Compound 1) or a salt thereof. Advantageous methods for obtaining the Compound 1 are also described, as well as pharmaceutical compositions containing it (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrodiline-2-carboxamide) cyclopropyl benzoic acid (Compound 1) or a pharmaceutically acceptable salt thereof is described for use as an EP4 receptor antagonist in the treatment of a pathology that involves the activities of prostaglandin E2 (PGE2) in its pathogenesis.
    Type: Grant
    Filed: July 4, 2019
    Date of Patent: August 8, 2023
    Assignee: ROTTAPHARM BIOTECH S.R.L.
    Inventors: Sabrina Pucci, Francesco Makovec, Lucio Claudio Rovati
  • Near infrared photocatalyst based on TiO-coated gold nanoparticles
    Patent number: 11712681
    Abstract: The invention relates to a method of preparing titanium dioxide-coated nanostars. Titanium precursors are hydrolyzed into crystalline TiO2 polymorphs at low temperatures, allowing the delicate morphology of the nanostars to be preserved while maintaining their desirable photocatalytic properties.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: August 1, 2023
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Laura Fabris, Fuat E. Celik, Supriya Atta, Ashley M. Pennington
  • Method and integrated process for the carboxylation of furan derived carboxylic acids to 2,5-furandicarboxylic acid
    Patent number: 11708343
    Abstract: A process for carboxylation of a furoate slurry to produce FDCA, especially 2,5-FDCA, includes the steps of: feeding a slurry containing a suspension fluid, furoate, a surfactant and an alkali metal carbonate to a carboxylation reactor; and feeding a flow of CO2 to the carboxylation reactor at flow conditions sufficient to suspend the slurry in the reactor and react the furoate with CO2 to form 2,5-FDCA. A fully integrated process is also disclosed.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: July 25, 2023
    Assignee: KSE, Inc.
    Inventors: James R. Kittrell, Carl R. Dupre, Keith D. Kittrell, Leonard T. McDonald, Jeffrey A. Kittrell
  • Continuous method for preparing carbonate esters
    Patent number: 11708345
    Abstract: In one embodiment, a continuous process for preparing organic carbonate solvent of Formula (I) as described herein comprises contacting a first reactant (an alcohol) with a reactive carbonyl source (carbonyldiimidazole (CDI) or an alkylchloroformate) in the presence of a catalyst in reaction stream flowing through a continuous flow reactor at temperature 20° C. to about 160° C. and at a flow rate providing a residence time in the range of about 0.1 minute to about 24 hours; collecting a reactor effluent exiting from the continuous flow reactor; recovering a crude product from the reactor effluent; and distilling the crude product to obtain the organic carbonate compound of Formula (I). In another embodiment, the first reactant is an epoxide and the carbonyl source is carbon dioxide.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: July 25, 2023
    Assignee: UCHICAGO ARGONNE, LLC
    Inventors: Trevor L. Dzwiniel, Krzysztof Pupek
  • N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors
    Patent number: 11708360
    Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: July 25, 2023
    Assignee: Pfizer Inc.
    Inventors: Brian Stephen Gerstenberger, Andrew Christopher Flick, Daniel Wei-Shung Kung, Vincent Michael Lombardo, James John Mousseau, Philippe Marcel Nuhant, Ralph Pelton Robinson, Jr., Daniel Copley Schmitt, Mark Edward Schnute, Atli Thorarensen, John Isidro Trujillo, Rayomand Jal Unwalla, Huixian Wu
  • Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof
    Patent number: 11708341
    Abstract: The present invention provides new methods for preparing compound 5, and pharmaceutically acceptable salts thereof, of structure Compound 5, or a pharmaceutically acceptable salt thereof, is an important intermediate in the synthesis of carfilzomib. The invention further provides methods of making a useful manganese catalyst that may be used in the epoxidation step of the present invention.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: July 25, 2023
    Inventors: Matthew Beaver, Sheng Cui, Xiangqing Shi
  • Toxic aldehyde related diseases and treatment
    Patent number: 11701331
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: July 18, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Crystalline hydrate of a JAK inhibitor compound
    Patent number: 11702415
    Abstract: Provided herein is a crystalline hydrate of the compound of formula 1: Also provides herein are pharmaceutical compositions comprising such crystalline hydrate, methods of using such crystalline hydrate to treat respiratory diseases, and processes useful for preparing such crystalline hydrate.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: July 18, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventor: Gene Timothy Fass